Vensobafusp alfa

{
  "id": "MLC-T-ONC-017490",
  "term": "Vensobafusp alfa",
  "field": "Oncology and biomedicine",
  "definition": "A fusion protein composed of an engineered immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5), with potential anti-inflammatory and immunomodulatory activities. Upon administration of a vensobafusp alfa, the anti-C5 antibody moiety targets and binds to terminal complement protein C5, thereby blocking the terminal complement pathway of complement activation. The FH1-5 moiety inhibits complement C3b deposition, thereby blocking the alternative pathway of complement activation. This inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction.",
  "synonyms": [
    "anti-C5 monoclonal antibody/FH1-5 fusion protein KP104",
    "anti-C5 monoclonal antibody/FH SCR 1-5 fusion protein KP104",
    "anti-C5 monoclonal antibody/complement factor H 1-5 domain fusion protein KP104"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/vensobafusp-alfa/"
}